THE PREVALENCE OF USING ASPIRIN BY DIABETIC PATIENTS VISITING PRINCE RASHID HOSPITAL

Introduction: Diabetes has various health impacts including inflammatory processes. Aspirin is used as anti-inflammatory treatment. Study objectives: to study the prevalence of aspirin use among diabetic patients. Methods and subjects: a retrospective study design was employed to collect data from study participants who attended internal medicine clinics at Rashid Prince Hospital. A total of 447 files of diabetic patients were reviewed. Study variables included age, gender, body mass index, aspirin intake, cardiac diseases, family history of cardiac diseases, and family history of diabetes. Data were analyzed using SPSS version 20. Study findings: the mean age of participants was 55.58+ 10.46 years, 47% of participants were males, and the mean of BMI was 39.18 which implied that participants in general were obese. Aspirin intake was reported by 43% of participants, about 76% of participants had cardiac disease, about 63% of patients had a family history of cardiac disease, and 31% had a family history of diabetes. Aspirin intake was associated significantly with gender (P=0.001) and females were more likely to intake aspirin. No other significant association was observed between aspirin intake and other study variables. Conclusion: the study findings showed that 43% of diabetic patients received aspirin as a treatment, while diabetic patients who had cardiac problems were 76% which implies that the prescription policy of aspirin needs to be revised

Development and characterization of k-carrageenan platforms as periodontal intra-pocket films

Purpose: To prepare emulsion-based Intrapocket polymeric films for the treatment of periodontitis. Method: Films were fabricated by dehydration of an emulsion containing k-carrageenan (KC) in aqueous phase and Compritol® 888 ATO (Compritol® ) or Dimodan® UJ (DU® ) or different ratios of both. The resulting films were characterized by mechanical texture analyser to determine Young’s modulus and tensile strength. Glass transition temperature (Tg) of the films was evaluated by dynamic mechanical and thermal analyser while surface morphology was evaluated using scanning electron microscope. In-vitro drug release was conducted in pre-warmed phosphate buffer. Bacterial adherence was assessed after 24 h. Results: Young’s modulus was highest for KC films to which no lipid was added (5.33 ± 0.38 GPa) and decreased following lipid incorporation. Tg was highest in KC films (106.25 ± 4.53 ° C) but decreased upon addition of lipids. The surface of KC was smooth but roughness increased with increasing Compritol® load. Drug release from KC films was complete (99.80 ± 8.43 %) after 2 h; however, upon adding lipid, the release was extended 8 h and was affected by lipid type and ratio. Microbiologic assay demonstrated noticeable reduction in viable count compared to control and was affected by lipid type and ratio. The film formulated from a combination of DU® and Compritol® in a ratio of 80:20 was strong, flexible and reduced microbial adherence. Moreover, it showed a smooth surface and extended release for over 8 h. Conclusion: Intra-pocket films were prepared by drying emulsion-based films. Resulted films were strong, flexible, prolonged drug release over 8 h and could lower bacterial growth. The prepared film may offer efficient treatment in periodontitis patients

SIMVASTATIN TREATMENT AMELIORATES DIABETIC TYPE 2 CONDITIONS THROUGH LOWERING THE CONCENTRATION OF PLASMA ICAM LEVELS

Diabetes type 2 is associated with other diseases including cardiovascular diseases. Obesity is a link between diabetes and cardiovascular diseases and associated with insulin resistance. Statins are used to reduce lipids and to lower the risk of cardiovascular diseases. The objective of the present study was to explore the effect of statin treatment on plasma levels of ICAM among diabetics. The study design was a prospective cohort clinical study. The study included 62 diabetic patients who were recruited from the Diabetes/Endocrine Clinics of the Prince Rashed Hospital. Data were collected from participants through a prepared questionnaire and laboratory findings of lipid profiles, glucose and ICAM levels. Study findings showed no significant variations between study and control groups at baseline level. At the end of the experiment, in study group, there were significant changes in some biochemical parameters such as ICAM level (p=0.005), cholesterol (0.019), and TG (0.025). The mean difference of study and control groups showed that significant variations were observed for the following variables ICAM (p<0.005), cholesterol (p=0.008), TG (p<0.005), and HDDL (p<0.005). Taken together, the present study showed that simvastatin therapy benefits diabetic patients even without hyperlipidemia through decreasing levels of ICAM-1, which have an inflammatory action and increase insulin resistance. It can be concluded that simvastatin is insulin sensitizer and works as anti-inflammatory agent

SIMVASTATIN TREATMENT AMELIORATES DIABETIC TYPE 2 CONDITIONS THROUGH LOWERING THE CONCENTRATION OF PLASMA ICAM LEVELS

Diabetes type 2 is associated with other diseases including cardiovascular diseases. Obesity is a link between diabetes and cardiovascular diseases and associated with insulin resistance. Statins are used to reduce lipids and to lower the risk of cardiovascular diseases. The objective of the present study was to explore the effect of statin treatment on plasma levels of ICAM among diabetics. The study design was a prospective cohort clinical study. The study included 62 diabetic patients who were recruited from the Diabetes/Endocrine Clinics of the Prince Rashed Hospital. Data were collected from participants through a prepared questionnaire and laboratory findings of lipid profiles, glucose and ICAM levels. Study findings showed no significant variations between study and control groups at baseline level. At the end of the experiment, in study group, there were significant changes in some biochemical parameters such as ICAM level (p=0.005), cholesterol (0.019), and TG (0.025). The mean difference of study and control groups showed that significant variations were observed for the following variables ICAM (p<0.005), cholesterol (p=0.008), TG (p<0.005), and HDDL (p<0.005). Taken together, the present study showed that simvastatin therapy benefits diabetic patients even without hyperlipidemia through decreasing levels of ICAM-1, which have an inflammatory action and increase insulin resistance. It can be concluded that simvastatin is insulin sensitizer and works as anti-inflammatory agent